Showing 3281-3290 of 5910 results for "".
- Sight Sciences Introduces SION—The First Bladeless Device Used in Goniotomyhttps://modernod.com/news/sight-sciences-introduces-the-sion-the-first-bladeless-device-used-in-goniotomy/2481040/Sight Sciences announced the launch of
- Staar Surgical Partners with Joe Jonas to Introduce New EVO ICLhttps://modernod.com/news/staar-surgical-partners-with-joe-jonas-to-introduce-new-evo-icl/2481024/Staar Surgical announced its partnership with singer, songwriter, and actor, Joe Jonas, to raise awareness of its EVO Visian Implantable Collamer Lenses (EVO). EVO is an FDA-approved vision correction lens designed for the correction/reduction of myopia and astigmatism. Mr. Jo
- Frontera Therapeutics Completes $160 Million Series B Financing to Fund Clinical Development and Manufacturing Capabilitieshttps://modernod.com/news/frontera-therapeutics-completes-160-million-series-b-financing-to-fund-clinical-development-and-manufacturing-capabilities/2480975/Frontera Therapeutics announced successful completion of a $160 million Series B funding round. In addition, Frontera announced that the FDA has accepted the company’s investigational new drug (IND) application to initiate a first-in-human clinical trial of FT
- Glasgow Eye Department Now Using Ocular Simulation Training Through DRV Systemhttps://modernod.com/news/glasgow-eye-department-now-using-ocular-simulation-training-through-drv-system/2480954/Simulation exposure is now an essential component of the Royal College of Ophthalmologists’ Ophthalmic Specialist Training curriculum prior to real-life surgery, according to a news release from Vision Engineering Group, a maker of ergonomic stereo optical and digital instruments. &nbs
- Nicox Announces Publication of NCX 470 Results Demonstrating Improvements to Ocular Hemodynamics and Retinal Cell Physiologyhttps://modernod.com/news/nicox-announces-publication-of-ncx-470-results-demonstrating-improvements-to-ocular-hemodynamics-and-retinal-cell-physiology-1/2480951/Nicox SA announced that the results from studies on the beneficial effects of NCX 470 in a nonclinical model of endothelin-1 (ET-1)-induced ischemia/reperfusion damage of the optic nerve head and retina have been published online in the peer-reviewed Journal of Ocular Pharmacology and Therape
- MeiraGTx Announces Topline Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Vision in XLRP Patientshttps://modernod.com/news/meiragtx-announces-positive-topline-data-from-the-mgt009-phase-12-clinical-study-demonstrating-safety-and-improvement-in-vision-in-xlrp-patients/2480936/MeiraGTx Holdings announced topline data from the phase 1/2 clinical study MGT009 (
- OliX Pharmaceuticals Subsidiary mCureX Announces mRNA Technology Collaboration with ToolGen for Rare Eye Diseasehttps://modernod.com/news/olix-pharmaceuticals-subsidiary-mcurex-announces-mrna-technology-collaboration-with-toolgen-for-rare-eye-disease/2480920/OliX Pharmaceuticals, a\ developer of RNAi therapeutics, announced that the company’s subsidiary, mCureX Therapeutics, has recently signed a contract for joint research with ToolGen to advance the development of gene therapy for rare eye diseases, leveraging mCureX’s mRNA technol
- CORE Study Shows Importance of Rub and Rinse Regimen for Coronavirus Removal from Contact Lens Materialshttps://modernod.com/news/core-study-shows-importance-of-rub-and-rinse-regimen-for-coronavirus-removal-from-contact-lens-materials/2480905/A new study conducted by the
- Aurion Biotech Appoints Michael Goldstein, MD, as President and Chief Medical Officerhttps://modernod.com/news/aurion-biotech-appoints-dr-michael-goldstein-as-president-and-chief-medical-officer/2480904/Aurion Biotech announced it has appointed Michael Goldstein, MD, as president and chief medical officer. Dr. Goldstein will lead the company’s clinical strategy, development and operations; medical affairs; and manufacturing and quality teams for its first product candidate, a cel
- NIH: Gene Therapy for Rare Eye Disease Safe But Lacks Efficacy in Early Trialhttps://modernod.com/news/nih-gene-therapy-for-rare-eye-disease-safe-but-lacks-efficacy-in-early-trial/2480896/A 28-patient phase 1 gene therapy clinical trial for the degenerative retinal disease Leber hereditary optic neuropathy (LHON) found no significant safety concerns; however, treatment failed to improve or slow vision loss, with even the highest dose. LHON affects the optic nerve, which carries vi